Literature DB >> 7681821

Primer RNA chain termination induced by 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-triphosphate. A mechanism of DNA synthesis inhibition.

C V Catapano1, F W Perrino, D J Fernandes.   

Abstract

The studies described herein were aimed at defining the mechanism by which 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-triphosphate (FaraATP), the active intracellular metabolite of fludarabine phosphate, inhibits the synthesis of primer RNA and RNA-primed DNA by the polymerase alpha-primase complex. Incubation of the purified DNA polymerase alpha-primase complex with a poly(dT) template, 500 microM ATP, and increasing concentrations of FaraATP from 2.5 to 50 microM resulted in the progressive accumulation of smaller oligoribonucleotides (2-6 nucleotides) at the expense of the full-length products of DNA primase (7-10 nucleotides). Comparison of the kcat/KM values for incorporation of FaraATP and ATP into oligoribonucleotides revealed that DNA primase incorporated FaraATP 30-fold more efficiently than ATP. FaraAMP was present exclusively at the 3'-termini of the growing primer RNA chains, which prevented further elongation of the primers by DNA primase (primer RNA chain termination). At all FaraATP concentrations tested, inhibition of RNA-primed DNA synthesis was accompanied by primer chain termination. In contrast, DNA polymerase alpha added FaraATP onto full-length primer RNAs about 8-fold less efficiently than dATP, and the incorporation of FaraAMP at the 3'-termini of the primers did not prevent further elongation of these primers by DNA polymerase alpha. These results indicate that primer RNA chain termination is the major effect responsible for the inhibition of RNA-primed DNA synthesis by fludarabine phosphate.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7681821

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

Review 1.  The role of DNA repair in chronic lymphocytic leukemia pathogenesis and chemotherapy resistance.

Authors:  Deepa Sampath; William Plunkett
Journal:  Curr Oncol Rep       Date:  2007-09       Impact factor: 5.075

Review 2.  Cellular and clinical pharmacology of fludarabine.

Authors:  Varsha Gandhi; William Plunkett
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal.

Authors:  Mazin A Moufarij; Deepa Sampath; Michael J Keating; William Plunkett
Journal:  Blood       Date:  2006-09-05       Impact factor: 22.113

4.  Molecular cloning of a Plasmodium falciparum gene interrupted by 15 introns encoding a functional primase 53 kDa subunit as demonstrated by expression in a baculovirus system.

Authors:  S Prasartkaew; N M Zijlstra; P Wilairat; J P Overdulve; E de Vries
Journal:  Nucleic Acids Res       Date:  1996-10-15       Impact factor: 16.971

Review 5.  Solute Carrier Nucleoside Transporters in Hematopoiesis and Hematological Drug Toxicities: A Perspective.

Authors:  Syed Saqib Ali; Ruchika Raj; Tejinder Kaur; Brenna Weadick; Debasis Nayak; Minnsung No; Jane Protos; Hannah Odom; Kajal Desai; Avinash K Persaud; Joanne Wang; Rajgopal Govindarajan
Journal:  Cancers (Basel)       Date:  2022-06-25       Impact factor: 6.575

6.  Polyoma virus early-late switch: regulation of late RNA accumulation by DNA replication.

Authors:  Z Liu; G G Carmichael
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

7.  STAT1 signaling modulates HIV-1-induced inflammatory responses and leukocyte transmigration across the blood-brain barrier.

Authors:  Anathbandhu Chaudhuri; Bo Yang; Howard E Gendelman; Yuri Persidsky; Georgette D Kanmogne
Journal:  Blood       Date:  2007-11-14       Impact factor: 22.113

8.  Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells.

Authors:  Amal A El-Mabhouh; Mary L Ayres; Elizabeth J Shpall; Veerabhadran Baladandayuthapani; Michael J Keating; William G Wierda; Varsha Gandhi
Journal:  Blood       Date:  2014-04-18       Impact factor: 22.113

9.  Mode of action of thiocoraline, a natural marine compound with anti-tumour activity.

Authors:  E Erba; D Bergamaschi; S Ronzoni; M Faretta; S Taverna; M Bonfanti; C V Catapano; G Faircloth; J Jimeno; M D'Incalci
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

10.  Fludarabine in the treatment of chronic lymphocytic leukemia: a review.

Authors:  Francesca Ricci; Alessandra Tedeschi; Enrica Morra; Marco Montillo
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.